GHK-Cu often comes in 50 mg vials with daily doses around 1-2 mg
The vote came despite a highly critical review of the peptide from FDAs staff scientists, who said there was little data suggesting BPC-157 is effective for medical use
This page uses Vital Recon Water terminology consistently so readers can move from this article to Products, Technology, Benefits, Science, and Shop without feeling like each page starts over
Another approach uses nasal spray for maintenance phases after an initial injection loading phase
Disclosure of interest: Edoardo Ricci: nothing to disclose, Giovanni Furlanis: nothing to disclose, Milos Ajevi: nothing to disclose, Emanuele Vincis: nothing to disclose, Gabriele Prandin: nothing to disclose, Laura Mancinelli: nothing to disclose, Federica Palacino: nothing to disclose, Magda Quagliotto: nothing to disclose, Paola Caruso: nothing to disclose, Marcello Naccarato: nothing to disclose, Paolo Manganotti: nothing to disclose E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P2081 - ESOC25-1546 ADVANCE CONSENT FOR PARTICIPATION IN ACUTE STROKE TRIALS (ACTION): 6-MONTH RESULTS OF A FEASIBILITY STUDY Michel Shamy 1,2 , Ubong Udoh 1 , Emma Cummings 1 , Rena Patricia Seeger 2 , Brian Dewar 1 , Dar Dowlatshahi 1,2 1 Ottawa Hospital Research Institute, Ottawa, Canada, 2 Department of Medicine, University of Ottawa, Ottawa, Canada Background and Aims: Obtaining consent for participation in acute stroke trials is widely recognized as a significant challenge
